Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin
- two drugs that have known senolytics properties - on physiological aging in older
individuals with depression or schizophrenia.